Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24322428 | 0.78 | PKM (0.61) | RAB9ANPC1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL24324205 | 0.74 | PKM (0.65) | RAB9ANPC1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL11479783 | 0.72 | KMT2A (0.67) | RAB9ANPC1ALDH1A1KMT2AMEN1 | |
| SCHEMBL5656878 | 0.71 | RAB9A (0.61) | RAB9ANPC1ALDH1A1KMT2AMEN1 | |
| SCHEMBL10753435 | 0.71 | PRCP (0.53) | RAB9ANPC1ALDH1A1KMT2AMEN1 | |
| SCHEMBL10753433 | 0.71 | PRCP (0.53) | RAB9ANPC1ALDH1A1KMT2AMEN1 | |
| SCHEMBL425351 | 0.70 | SMN1; SMN2 (0.57) | RAB9ANPC1ALDH1A1KMT2AMEN1 | |
| SCHEMBL425352 | 0.70 | RAB9A (0.60) | RAB9ANPC1ALDH1A1KMT2AMEN1 | |
| SCHEMBL9851181 | 0.69 | KMT2A (0.58) | RAB9ANPC1ALDH1A1KMT2AMEN1 | |
| SCHEMBL6202067 | 0.69 | KMT2A (0.52) | RAB9ANPC1ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | RAB9A 435/4885NPC1 2900/4885ALDH1A1 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.